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Abstract
Background: Systemic effects of chronic obstructive pulmonary disease (COPD) significantly
contribute to severity and mortality of the disease. We aimed to develop a COPD/emphysema
model exhibiting systemic manifestations of the disease.
Methods: Female NMRI mice were treated 5 times intratracheally with porcine pancreatic elastase
(emphysema) or phosphate-buffered saline (control). Emphysema severity was quantified
histologically by mean linear intercept, exercise tolerance by treadmill running distance, diaphragm
dysfunction using isolated muscle strips, pulmonary hypertension by measuring right ventricular
pressure, and neurohumoral activation by determining urinary norepinephrine concentration.
Results: Mean linear intercept was higher in emphysema (260.7 ± 26.8 μm) than in control lungs
(24.7 ± 1.7 μm). Emphysema mice lost body weight, controls gained weight. Running distance was
shorter in emphysema than in controls. Diaphragm muscle length was shorter in controls
compared to emphysema. Fatigue tests of muscle strips revealed impaired relaxation in emphysema
diaphragms. Maximum right ventricular pressure and norepinephrine were elevated in emphysema
compared to controls. Linear correlations were observed between running distance changes and
intercept, right ventricular weight, norepinephrine, and diaphragm length.
Conclusion: The elastase mouse model exhibited severe emphysema with consecutive exercise
limitation, and neurohumoral activation. The model may deepen our understanding of systemic
aspects of COPD.
Background
Chronic obstructive pulmonary disease (COPD) is a
major cause of death and disability worldwide [1]. The
treatment of COPD improves lung function, yet it is
unlikely to slow the steady downhill course of the disease
or even reduce mortality [2]. Notably exercise intolerance
is a central symptom in COPD patients and closely relates
to quality of life and prognosis [3-5].
Although COPD affects primarily the lungs it recently
became clear that systemic effects of COPD significantly
contribute to its severity and mortality [1,6]. These sys-
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temic effects relate to tobacco smoke, chronic inflamma-
tion and oxidative stress [1,7,8], peripheral as well as
diaphragm muscle dysfunction [9], pulmonary hyperten-
sion [10], the renin-angiotensin system [11] and the auto-
nomic nervous system [12,13].
Although no single animal model recapitulates human
COPD in its entirety, animal models are fundamental to
COPD research [14]. Instillation of elastase into animal
lungs has been a reliable means of quickly generating air-
space enlargement [15]. The elastase-induced emphysema
mouse model is well established [15-18] and with the
advent of genetic engineering offers variable opportuni-
ties to dissect pathogenetic pathways [19].
A number of studies, mainly in emphysematous hamsters,
have investigated the effect of exercise on ventilatory mus-
cle, pulmonary function and pulmonary hypertension
[18,20-22]. However, exercise capacity or activity has not
been evaluated in these studies. One study has shown that
emphysema causes skeletal muscle dysfunction but no
effect on activity was noted [23]. Thus, to our knowledge,
exercise intolerance as well as sympathetic activation has
never been demonstrated in an emphysema model.
We aimed to develop a murine emphysema model exhib-
iting systemic manifestations of COPD. We hypothesized
that severe pulmonary emphysema results in exercise
intolerance and neurohumoral activation. Furthermore
we aimed to investigate as additional parameters weight
loss, diaphragm dysfunction, and pulmonary hyperten-
sion.
Methods
Study protocol
The investigations complied with the National Research
Council guide for the care and use of laboratory animals
(National Academy Press, Washington, D.C. 1996). The
initial study protocol comprised of a single elastase
administration as detailed below (protocol 1). This proto-
col was extended in protocol 2 to a total of 5 elastase
administrations with 1 week as recovery period between
individual instillations. Each protocol started with 12
mice for elastase treatment and 8 control mice. In a sec-
ond series of protocol 2 another 12 elastase and 8 control
mice were treated to gain additional information on dia-
phragm function and right ventricular mass and haemo-
dynamics 6 months after the last elastase treatment.
Experimental animals
Female NMRI mice were used (body weight 20–25 g, Har-
lan-Winkelmann, Borchen, Germany). NMRI mice repre-
sent a robust outbred mouse strain that possesses higher
endogenous anti-protease activity as, e.g., mice from the
C57 background [24]. Thus, we used NMRI mice, assum-
ing they would exhibit better tolerance toward the acute
toxic effects of intratracheal elastase administration.
Female mice were chosen, because they usually gain less
weight than males during prolonged observation periods.
Human COPD occurs more frequently in men than
women. This, however, does not reflect intrinsic biologi-
cal differences but is generally accepted to be a manifesta-
tion of differing smoking behaviour.
Emphysema induction
For elastase instillation mice were anaesthetized with iso-
flurane, intubated orotracheally and ventilated via venti-
lator/respirator (Mini-Vent Small Animal Ventilators,
Harvard Apparatus/Hugo Sachs Elektronik, March-Hug-
stätten, Germany). Experimental animals received 5 U/
100 g body weight (protocol 1) and 3.3 U/100 g body
weight (protocol 2) porcine pancreatic elastase (Sigma-
Aldrich, Taufkirchen, Germany) dissolved in 50 μl phos-
phate-buffered saline solution (PBS). Control animals
received 50 μl of PBS. The respective solution was admin-
istered intratracheally via a tube followed by 200 μl of air
for an even distribution of the liquid throughout both
lungs. Afterwards mice were kept on a warm plate (30°C)
until restoration of spontaneous breathing and extubated.
Body weight, norepinephrine concentration, and exercise 
tolerance
Mice were maintained on a 12/12-hour light-dark cycle
and were fed ad libitum. The body weight was determined
daily throughout the study period till to the final experi-
ments. At baseline as well as 7 days after the single (pro-
tocol 1) or last (protocol 2) intervention, each mouse was
placed in a metabolic cage (Tecniplast GmbH, Wilhelm-
shaven, Germany) for 24 hours, provided with food and
water ad libitum. Urine was collected, acidified and stored
at -70°C until determination of norepinephrine concen-
tration (NE). NE was measured by high-performance liq-
uid chromatography and normalised to urinary
creatinine.
For determination of the exercise tolerance treadmill exer-
cise tests were performed using a motorized rodent tread-
mill equipped with a shock-plate incentive (Exer-6M
Open Treadmill, Columbus Instruments, Columbus,
Ohio, USA). To habituate the mice to the treadmill three
exercise tests were performed with one day of rest between
the tests within one week before starting the experiments.
The final exercise test was used as baseline test and the dis-
tance covered calculated as the time-speed-integral up to
the point of exhaustion. Six days after each (protocol 1
and 2) intubation procedure further exercise tests for com-
parison with baseline were performed. Treadmill speed
(start value: 10 m/min) was increased by 1 m/min every
two minutes with no upper limit. The slope of the tread-
mill was kept constant at 5°. Criteria for the end of the testRespiratory Research 2009, 10:7 http://respiratory-research.com/content/10/1/7
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were exhaustion of the animals defined as inability to
return to the treadmill belt despite repetitive electric stim-
ulation.
Organ preparation and assessment of functional lung 
parameters
During the third week after the (final) intratracheal treat-
ment, organ preparation and measurement of lung func-
tion parameters for the calculation of static compliance
were performed. Mice were anaesthetized deeply and their
thorax opened. Blood was collected by cardiac puncture to
achieve a largely bloodless lung. A tracheal incision was
performed facilitating the insertion and fixation of a
blunted cannula. The trachea and both lungs were mobi-
lized and removed from the thorax in a whole. For stable
experimental conditions the lungs were submerged in a
water bath. The cannula was connected with an infusion
pump and the lungs were inflated twice at a rate of 15 ml/
h to a maximum airway pressure of 25 cm H2O measured
with an interposed pressure transducer (Linearcorder
Mark 7, Harvard Apparatus/Hugo-Sachs-Elektronik,
March-Hugstetten, Germany). Then the tubing system
was opened to the atmosphere, allowing air to leak via a
cannula out of the system. The corresponding volume-
pressure curves were digitally recorded and served as basis
for the calculation of the static compliance. Afterwards,
the right lung was kept in 10% formalin fixation liquid at
a constant pressure of 25 cm H2O for at least 24 hours, fol-
lowed by histological assessment.
Histological analysis
The fixed lungs were embedded in paraffin and sections of
five micrometers were cut. Tissue sections were stained
with haematoxylin and eosin. For morphometric analysis
a computerized microscope with a high-resolution video
camera (BX S1, Olympus, Tokyo, Japan, magnification
10×) was used. For mean linear intercept (Lm) determina-
tion 10 sagittal sections spanning the entire lung and con-
taining apical as well as basal areas of the organ were
randomly selected from each mouse. The Lm as indicator
of air space size was calculated from counting lines of
defined length as previously described [25]. Briefly the
lines were randomly placed on every of the 10 lung sec-
tions and the number of intercepts crossing the lines
counted. The mean linear intercept is calculated from the
length of the lines multiplied by the number of the lines
divided by the sum of all counted intercepts.
Determination of right ventricular haemodynamics and 
mass
In vivo haemodynamic analysis was performed using a 1.4
F microtip catheter (model SPR-839, Millar Instruments
Inc., Houston, USA) placed through the right ventricular
(RV) apex in the open-chest, isoflurane-anesthetized
mouse and positioned along the longitudinal axis of the
RV to record chamber pressure by micromanometry.
Afterwards mice were euthanized with isoflurane and
lungs and hearts were rapidly excised. Right and left ven-
tricular weight were measured and normalized with
regard to tibia length. This has proven superior to normal-
ization with regard to body weight in animals of differing
weights [26].
Diaphragm muscle function
Following excision of hearts and lungs as described above
the empty chest was rinsed with ice-cold modified Krebs-
Henseleit (K-H) buffer solution containing (in mM): Na+
140.5, K+ 5.1, Mg2+ 1.2, Ca2+ 0.25, Cl- 124.9, SO4
2- 1.2,
PO4
3- 2.0, HCO3
- 20, glucose 10, butanedionemonoxime
(BDM) 20, pH 7.4. A ring of the chest wall with the dia-
phragm attached was excised and cleared from blood in
ice-cold K-H buffer solution. Longitudinal muscle strips
of 0.8 – 1 mm width were dissected from the left posterior
quadrant of the diaphragm such that on the one end a
piece of the adjacent rib and on the other end a piece of
the tendinous center of the diaphragm were left. Prepara-
tions were mounted isometrically between a wire loop
connected to a force transducer (Scientific Instruments,
Heidelberg, Germany) and a hook connected to a
micrometer drive for length adjustment and superfused at
37°C with K-H solution equilibrated with 95% O2/5%
CO2. The solution was replaced with BDM-free K-H solu-
tion containing Ca2+ at 1.25 mmol/L, and electrical field
stimulation was initiated at 1 Hz using biphasic pulses of
4 ms duration and 5 V amplitude (Stimulator STIM1, Sci-
entific Instruments, Heidelberg, Germany). Preparations
were stretched to a passive tension of 1 mN/mm2 and
allowed to functionally stabilize for 30 min. 3-s trains of
electrical stimuli in 10-Hz increments (covering the range
10 – 120 Hz) were applied once per minute and the force
response was recorded on a computer using LabView
(National Instruments). After another 30-min period for
recovery, a fatigue test was initiated consisting of 100
repetitive trains of stimuli at 100 Hz, 250 ms duration, 1/
s, during which tetanic force and its decline due to fatigue
were recorded. All force values were normalized to the
cross-sectional area of the respective muscle preparations
(mN/mm2) [27].
Statistical analysis
All variables were tested for normal distribution and are
given as mean ± SEM. To compensate for group differ-
ences at baseline, body weight and exercise performance
were expressed as percentage of the respective baseline
value. For the in-group comparison of the relative base-
line value versus the relative value after the final intuba-
tion procedure a paired t-test was performed. For
comparison between control and the respective emphy-
sema groups an unpaired t-test was performed. For com-
parison of control and the two emphysema groups treated
by different protocols a one-way ANOVA with Bonfer-
roni's correction was applied. For the combined groupRespiratory Research 2009, 10:7 http://respiratory-research.com/content/10/1/7
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(emphysema and control) and the distinct groups the
change in running distance was correlated to various
parameters using the Pearson coefficient. Two-tailed tests
were used and significance was accepted at a value of p <
0.05.
Results
Single administration
During protocol 1 a total of six mice treated with elastase
died. This was caused twice by pneumothorax and in four
cases by haemorrhage evidenced by macroscopic evalua-
tion. Two control mice died during the intubation proce-
dure. Thus, a total of six mice in each group were available
for analysis.
Repetitive administration
During the first series of protocol 2 five elastase treated
mice and one control mouse died. Haemorrhage caused
death in one mouse and pneumothorax in another in the
elastase group. A total of three mice in the elastase group
and one more in the control group died during the intu-
bation procedure. Thus, finally seven mice in each group
were available for analysis. In the second series of proto-
col 2 three mice in the elastase group (pneumothorax in
two mice and haemorrhage in one mouse) and one
mouse in the control group (during intubation proce-
dure) died. Thus, evaluation of diaphragm and RV was
conducted from nine elastase treated mice and seven con-
trol mice.
Histology
The mean linear intercept was significantly higher by sin-
gle elastase administration compared to control (108.0 ±
14.7 μm vs. 30.2 ± 0.8 μm; p < 0.05). Repetitive elastase
instillation resulted in a more pronounced emphysema,
reflected by a significantly higher mean linear intercept
(260.7 ± 26.8 μm) as compared to the single treatment
regimen (p < 0.0001; table 1, for example see figure 1).
Body weight
The single administration protocol had no significant
effect on the body weight change neither of the elastase-
treated nor of the control mice. After the repetitive admin-
istration protocol, however, elastase-treated mice lost
body weight compared to baseline (94.9 ± 2.4%), whereas
control mice gained weight (110.4 ± 2.8%), resulting in a
significant difference between emphysema and control
animals (p = 0.001).
Norepinephrine concentration
The single administration protocol did not result in a sig-
nificant difference of urinary norepinephrine concentra-
tion between the elastase and control group (18.3 ± 1.3
μg/l/mg/100 ml creatinine vs. 16.9 ± 0.8 μg/l/mg/100 ml
creatinine; p = 0.36). In contrast, the repetitive adminis-
tration protocol lead to a significant difference in nore-
pinephrine concentration at follow-up between elastase
and control animals (p < 0.01; figure 2).
Exercise tolerance
No significant exercise performance change was observed
between elastase and control mice after the single admin-
istration protocol. Following repetitive elastase instilla-
tion, however, the relative running distance after the last
elastase instillation was significantly reduced in the
elastase group (29.7 ± 8.7% of baseline; p < 0.0001) com-
pared with the control group (79.1 ± 14.0% of baseline; p
= n. s.; elastase vs. control p = 0.01; figure 3).
Correlation analysis for the combined groups revealed
linear relationships between changes in running distance
and changes in body weight (r = 0.76; p < 0.01), mean lin-
ear intercept (r = -0.64; p < 0.05), right ventricular weight
(r = -0.71; p < 0.01), diaphragm length (r = 0.69; p <
0.01), and norepinephrine concentration at follow-up (r
= -0.59; p < 0.05; figure 4). Correlation analysis in the dis-
tinct groups, showed a trend for changes in running dis-
Table 1: Lung, heart and diaphragm parameters
elastase controls P value
Mean linear intercept [μm] 260.7 ± 26.8 24.7 ± 1.7 <0.001
static compliance [μl/cm H2O] 185.1 ± 17.1 48.5 ± 5.0 <0.001
Diaphragm muscle length [mm] 5.1 ± 0.1 6.8 ± 0.3 <0.001
Tibia length [mm] 19.6 ± 0.2 19.9 ± 0.1 0.2
Heart weight [mg] 145.4 ± 5.4 148.7 ± 6.4 0.7
Right ventricular weight [mg] 44.0 ± 3.2 34.3 ± 3.2 0.055
Heart weight/tibia length [mg/mm] 7.4 ± 0.3 7.5 ± 0.3 0.95
RV weight/tibia length [mg/mm] 2.2 ± 0.2 1.7 ± 0.2 <0.05
dp/dt max [mmHg/s] 2389 ± 102 1143 ± 159 <0.0001
RV peak systolic pressure [mmHg] 38.8 ± 1.3 21.8 ± 1.2 <0.0001
RV end-diastolic pressure [mmHg] 4.6 ± 0.5 3.1 ± 0.3 <0.05
Lung parameters derived from series 1 of protocol 2; diaphragm muscle length, tibia length, heart weight and hemodynamics derived from series 2 
of protocol 2Respiratory Research 2009, 10:7 http://respiratory-research.com/content/10/1/7
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tance and changes in body weight (r = 0.74; p < 0.1), as
well as right ventricular weight (r = -0.68; p < 0.1) in the
elastase group, but no such trend in the control group.
Static compliance
Single elastase instillation resulted in a non-significantly
higher static compliance of 66.3 ± 3.9 μl/cm H2O com-
pared to controls with 43.5 ± 5.2 μl/cm H2O. Compared
to the single treatment regimen the static compliance was
significantly higher after repetitive elastase instillation (p
< 0.0001 vs. single elastase treatment; table 1).
RV haemodynamics and mass
Evaluation of the RV parameters was only done in repeti-
tively treated animals 6 months after the last elastase treat-
ment. RV end-diastolic pressure was mildly, but not
significantly, higher in elastase-treated compared to con-
trol mice. RV peak systolic pressure, however, was nearly
doubled in emphysema compared to control mice (p <
0.0001, table 1 and figure 5), indicating pulmonary
hypertension. RV mass normalized to tibia length of the
animals was significantly higher in emphysema animals
than in controls (p < 0.05; table 1), confirming RV pres-
sure-induced hypertrophy.
Diaphragm
Diaphragm evaluation was conducted only in repetitively
treated animals 6 months after the last elastase treatment.
Representative photomicrographs showing morphology of lungs treated with phosphate buffered salt (normal lung morphol- ogy; upper panel), single elastase application (lower panel on the left), and repetitive elastase instillations over a period of 5  weeks (pronounced emphysematous changes; lower panel on the right) Figure 1
Representative photomicrographs showing morphology of lungs treated with phosphate buffered salt (normal 
lung morphology; upper panel), single elastase application (lower panel on the left), and repetitive elastase 
instillations over a period of 5 weeks (pronounced emphysematous changes; lower panel on the right).
Norepinephrine (NE) concentration in urine of elastase  treated mice (protocol 2) and controls Figure 2
Norepinephrine (NE) concentration in urine of 
elastase treated mice (protocol 2) and controls. 
Repetitive administration of elastase lead to a significantly 
higher norepinephrine concentration at follow-up compared 
to control animals.
p<0.01
0
5
10
15
20
25
30
baseline   follow-up
elastase [n=7]
baseline   follow-up
control [n=7]
n
o
r
e
p
i
n
e
p
h
r
i
n
e
/
c
r
e
a
t
i
n
i
n
e
 
i
n
 
u
r
i
n
e
[
μ
g
/
l
 
/
 
m
g
/
1
0
0
m
l
]
p < 0.01 Respiratory Research 2009, 10:7 http://respiratory-research.com/content/10/1/7
Page 6 of 10
(page number not for citation purposes)
Diaphragm muscle length was significantly shorter in
elastase-treated compared to control mice (p < 0.001;
table 1). The force-frequency relationship as well as the
developed tension during the fatigue test of isolated dia-
phragm muscle strips did not differ between elastase
treated mice and control mice. However, during the
fatigue test diaphragm muscle strips of elastase-treated
mice showed incomplete relaxation, while relaxation was
unimpaired in preparations from control mice (p < 0.01;
Figure 6)
Discussion
The described model of pulmonary emphysema for the
first time allows investigating exercise intolerance as a
central symptom of COPD. Furthermore, our murine
model shows systemic manifestations, namely reduced
body weight, diaphragm dysfunction, sympathetic activa-
tion, and pulmonary hypertension that contribute to the
pathophysiology and clinical appearance of COPD in
man. Particularly neurohumoral activation in COPD to
our knowledge has never before been observed in an ani-
mal model [13].
Single versus repetitive elastase application
Elastase instillation was established > 40 years ago to
develop a model of emphysema in hamsters [15,18]. The
desired effect of elastase is limited to a narrow window of
dosage, below which no significant loss of alveoli is
observed, whereas a higher dose results in severe pulmo-
nary haemorrhage [28]. Furthermore, it has been shown
that elastase administration results in a heterogeneous
effect on alveolar size and diameter [29]. Not surprisingly,
therefore, despite clear structural and functional evidence
of lung emphysema following a single administration of
elastase we failed to observe general manifestations that
would confirm the validity of this approach to cause a
state reminiscent of human disease. Thus, we altered the
study protocol to repetitive administration of reduced sin-
gle doses of elastase. Repetitive intratracheal papain instil-
lation has previously been described in rats with a high
mortality (63 of 80) [30].
Emphysema
Several animal models (including dogs, guinea pigs, mon-
keys, sheep, hamster, mice and rats) have been estab-
lished to study COPD and emphysema [14,15,18,31]. In
our study the mean linear intercept after single elastase
treatment of mice was comparable to values in the litera-
ture ranging from 35 to 85 μm [17,32-35]. Furthermore
the increase in compliance following elastase corrobo-
rates previous work [35]. Repetitive elastase administra-
tion, however, resulted in a significantly higher mean
linear intercept and thus more severe emphysema than
the single treatment regimen. The histological results were
accompanied by a more severe functional change of the
lung in repetitively treated mice as reflected by a signifi-
cantly higher static compliance. Instillation of elastase
into animal lungs is not expected to provide information
on upstream events such as inflammation [36]. Yet, it was
recently noticed that elastase leads to endogenous inflam-
mation and further lung destruction over the ensuing
weeks [14,37].
Body weight
The repetitive elastase treatment protocol in this study
resulted in a slight reduction of the body weight, whereas
in controls body weight increased with advancing age and
size of the animals. In most previous studies with single
elastase application in hamsters there was no significant
change in body weight [23,31,38,39]. Weight loss occurs
in about 10 to 15% of patients with mild to moderate
COPD and about 50% of patients with severe disease
[40]. Low body weight is an important systemic manifes-
tation of COPD and is associated with increased mortality
[3]. Since we have not evaluated body composition, food
intake or daily activity, we can not comment on the causes
of weight loss in our mice.
Sympathoexcitation
Recent data demonstrate that COPD patients exhibit
marked neurohumoral activation [12]. The cause of this
activation is not entirely clear, but the chemoreflex,
baroreflex, lung inflation reflex and muscle metabore-
flexes might contribute. Given the established negative
connotations of neurohumoral activation in heart failure
and other diseases, neurohumoral activation in COPD
Exercise tolerance of elastase treated (protocol 2) and con- trol mice Figure 3
Exercise tolerance of elastase treated (protocol 2) 
and control mice. Shown are the running distances at the 
follow-up evaluations after the respective elastase treatment 
normalized to the baseline running distance (week 0). The 
relative running distance after the last elastase instillation was 
significantly shorter in the elastase group than in the control 
group.
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may well have negative consequences, namely on inflam-
mation, cachexia, skeletal muscle dysfunction and cardio-
vascular disease [13]. In the present study, we found for
the first time a significant increase of urinary norepine-
phrine concentration in emphysematous animals und
thus corroborate previous findings in COPD patients
[8,13]. Our model may thus serve to unravel the relation-
ship between sympathoexcitation and COPD.
Exercise capacity
The assessment of COPD severity based on lung function
bears limitations. Therefore, additional markers for
assessment of the disease have been searched for [1].
Recently the BODE index, which includes body mass
index, airflow obstruction, dyspnoea and exercise capac-
ity, has been shown to be a stronger predictor of COPD
prognosis than FEV1 [3].
Correlation analysis between changes in running distance and body weight change, right ventricular weight, norepinephrine  concentration, and diaphragm length Figure 4
Correlation analysis between changes in running distance and body weight change, right ventricular weight, 
norepinephrine concentration, and diaphragm length.
p<0.01  p<0.01 
p<0.05 p<0.01 Respiratory Research 2009, 10:7 http://respiratory-research.com/content/10/1/7
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In previous emphysema animal models the effect of exer-
cise on pulmonary function was studied. However, exer-
cise capacity so far has not been evaluated [18,20-23,31].
In one of these studies elastase treated hamsters showed
decreased oxygenation during exercise [31]. Another
study found no differences in the level of activity [23]. In
our study, exercise capacity was significantly lower in
elastase-treated mice than in controls. As exercise capacity
integrates abnormalities of pulmonary, cardiovascular
and muscle function in a single measurement, the
observed reduction may reflect emphysema severity, but
may also originate from reduced function of other organ
systems as detailed above. In our study correlation analy-
sis reveals a relationship of borderline significance
between exercise limitation and mean linear intercept, RV
weight, and norepinephrine concentration. This analysis
does not prove causality. However, our findings parallel
clinical data and pathophysiological concepts explaining
exercise limitation in COPD [1,3].
Right ventricle
Similar to patients with COPD, our mice with severe pul-
monary emphysema showed increased RV pressures as
indicator for pulmonary hypertension and consecutively
increased RV mass [41], indicating RV pressure-induced
hypertrophy. Pulmonary hypertension has been noted
previously in animal emphysema models [18,30]. Reduc-
tion of the capillary bed following pulmonary emphy-
sema contributes to increase in pulmonary vascular
pressure [10]. However, since we have not evaluated oxy-
gen saturation we cannot comment whether hypoxemia
contributes to the increase in pulmonary pressure.
Diaphragm dysfunction
In patients with COPD, functional impairment of the dia-
phragm is present and associated with accelerated muscle
protein degration [42]. The underlying etiology is poorly
understood. Mechanical factors such as hyperinflation
induced increased contractile activity of the diaphragm or
systemic inflammation and oxidative stress might contrib-
ute [42,43].
In accordance with previous human and animal data we
found a reduced diaphragm muscle length in the emphy-
sema mice compared to controls [4,38]. The importance
of diaphragm muscle length for respiratory breathing
effort is highlighted by the positive effects of lung volume
reduction surgery [4,38]. In our study evaluation of dia-
phragm function revealed impaired relaxation with pre-
served contractile function in the elastase-treated mice.
Impaired relaxation of diaphragm muscle is generally
considered an early index of respiratory muscle fatigue
[44]. Especially at high breathing rates diaphragm relaxa-
tion is crucial, because the diaphragm must return to its
optimal muscle length between each inspiration and
because diaphragmatic perfusion depends on rapid relax-
ation [44].
Limitations
No single animal model recapitulates human COPD in its
entirety [15]. Mouse lung structure is not identical to
humans. For example mice have few submucosal glands,
much less airway branching, and they do not contain res-
piratory bronchioles – the initial site of centriacinar
emphysema in man [14]. However, the mouse provides a
good choice for an animal model because the mouse
In vivo analysis of peak systolic RV pressure (RVP max) and  RV end-diastolic pressure (RVEDP) of control and elastase  treated (protocol 2) mice, indicating pulmonary hypertension  of emphysematous mice Figure 5
In vivo analysis of peak systolic RV pressure (RVP 
max) and RV end-diastolic pressure (RVEDP) of con-
trol and elastase treated (protocol 2) mice, indicating 
pulmonary hypertension of emphysematous mice.
p=n. s. p<0.001
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Tension at rest normalized to maximum tetanic tension of  isolated longitudinal muscle strips of control and emphysema  (protocol 2) mice using repetitive trains of stimuli Figure 6
Tension at rest normalized to maximum tetanic ten-
sion of isolated longitudinal muscle strips of control 
and emphysema (protocol 2) mice using repetitive 
trains of stimuli. Diaphragm muscle strips of elastase 
treated mice showed incomplete relaxation, while relaxation 
was unimpaired in preparations from control mice.Respiratory Research 2009, 10:7 http://respiratory-research.com/content/10/1/7
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genome has been extensively studied and close similari-
ties exist with the human genome [19].
Elastase instillation models are rather crude models
inducing massive lung injury with a single or repetitive
administration of the protease. This does not reflect the
continuous low grade inflammatory process, which is
believed to underlie smoking related emphysema
[14,16,45]. However, elastase-induced emphysema mod-
els can be useful for studying therapeutic strategies follow-
ing the insult [14,16].
Conclusion
This is the first study showing systemic effects of COPD
with pulmonary emphysema such as sympathoexcitation
and exercise intolerance in an elastase mouse model. The
model may help to deepen the not-well characterized
impact of neurohumoral activation on pathogenesis and
course of COPD with emphysema.
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